Technology Assessment Saves $2M in Infrastructure Investment
Comprehensive evaluation prevents costly mistakes and optimizes resource allocation
Client Overview
An emerging biotech company with fresh Series A funding needed to build their bioinformatics infrastructure. They were about to commit $3M to commercial software licenses and hardware without a clear understanding of alternatives or long-term implications.
The Situation
The company's leadership, primarily wet-lab scientists, had received proposals from multiple vendors for:
- Commercial variant calling and annotation software ($800K/year)
- Proprietary pipeline management platform ($400K/year)
- On-premise HPC cluster ($1.2M upfront + $300K/year maintenance)
- Commercial genome browser licenses ($150K/year)
- Data management system ($250K/year)
Total 3-year cost: $8.1M
They engaged SyncBio for an independent technology assessment before committing to these investments.
Our Assessment Approach
1. Requirements Analysis
Conducted detailed interviews with stakeholders to understand:
- Current Workload: 50 whole genomes/month, scaling to 200/month in 18 months
- Analysis Types: Germline variant calling, somatic mutation detection, RNA-seq
- Team Composition: 2 bioinformaticians, 15 wet-lab scientists, no dedicated IT
- Regulatory Needs: Research-grade initially, clinical validation planned in 2 years
- Budget Constraints: Limited runway, need to optimize burn rate
2. Technology Stack Evaluation
Pipeline Management:
Vendor Proposal: Proprietary platform ($400K/year)
Our Recommendation: Nextflow + nf-core pipelines (open-source)
- Cost: $0 for software, $50K for initial setup and training
- Benefits: Community-supported, 100+ pre-built pipelines, cloud-native
- Savings: $1.15M over 3 years
Variant Calling & Annotation:
Vendor Proposal: Commercial suite ($800K/year)
Our Recommendation: GATK + Ensembl VEP + ClinVar (open-source)
- Cost: $0 for software, $40K for pipeline development
- Benefits: Industry-standard tools, full customization, no vendor lock-in
- Savings: $2.36M over 3 years
Compute Infrastructure:
Vendor Proposal: On-premise HPC ($1.2M + $300K/year)
Our Recommendation: AWS Batch with Spot Instances
- Cost: ~$180K/year for current workload, scales with usage
- Benefits: No upfront investment, elastic scaling, no maintenance burden
- Savings: $1.44M over 3 years
Data Storage:
Vendor Proposal: Proprietary data management ($250K/year)
Our Recommendation: AWS S3 with Intelligent-Tiering + PostgreSQL
- Cost: ~$60K/year for 500TB with automatic tiering
- Benefits: Unlimited scalability, built-in redundancy, lifecycle policies
- Savings: $570K over 3 years
Genome Browser:
Vendor Proposal: Commercial licenses ($150K/year)
Our Recommendation: IGV + JBrowse 2 (open-source)
- Cost: $0 for software, $20K for custom deployment
- Benefits: Full-featured, widely used, customizable
- Savings: $430K over 3 years
3. Architecture Design
Designed cloud-native architecture optimized for their workload:
Compute Layer:
- AWS Batch: Managed job scheduling and execution
- Spot Instances: 70% cost savings on compute
- Auto-scaling: Scale from 0 to 500 cores based on demand
- Containerization: Docker containers for reproducibility
Storage Layer:
- S3 Intelligent-Tiering: Automatic cost optimization
- Glacier Deep Archive: Long-term storage at $1/TB/month
- EFS: Shared filesystem for active analysis
- Lifecycle Policies: Automated data archival
Data Layer:
- RDS PostgreSQL: Metadata and sample tracking
- ElastiCache: Caching for frequent queries
- Athena: SQL queries on S3 data
Application Layer:
- Web Portal: React-based UI for scientists
- API Gateway: RESTful API for programmatic access
- Lambda Functions: Serverless data processing
4. Pipeline Recommendations
Identified optimal open-source pipelines for each analysis type:
- Germline Variant Calling: nf-core/sarek (GATK best practices)
- Somatic Variant Calling: Custom Nextflow pipeline with Mutect2, Strelka2, VarDict
- RNA-seq: nf-core/rnaseq (STAR + Salmon + DESeq2)
- Quality Control: MultiQC for aggregated reports
- Annotation: Ensembl VEP + ClinVar + gnomAD
5. Cost Projection Model
Built detailed 3-year cost model with growth scenarios:
| Component | Vendor Proposal (3yr) | Our Recommendation (3yr) | Savings |
|---|---|---|---|
| Pipeline Management | $1,200,000 | $50,000 | $1,150,000 |
| Variant Calling Software | $2,400,000 | $40,000 | $2,360,000 |
| Compute Infrastructure | $2,100,000 | $660,000 | $1,440,000 |
| Data Storage | $750,000 | $180,000 | $570,000 |
| Genome Browser | $450,000 | $20,000 | $430,000 |
| Implementation & Training | $200,000 | $150,000 | $50,000 |
| Total 3-Year Cost | $8,100,000 | $1,100,000 | $7,000,000 |
Key Recommendations
- Avoid Vendor Lock-in: Use open-source tools with strong community support instead of proprietary platforms
- Cloud-First Strategy: Leverage cloud elasticity instead of upfront hardware investment
- Start Simple: Begin with proven nf-core pipelines, customize only when necessary
- Optimize for Spot: Design pipelines to tolerate interruptions, save 70% on compute
- Automate Data Lifecycle: Implement tiering policies to minimize storage costs
- Build Internal Expertise: Invest in training rather than outsourcing everything
- Plan for Clinical: Design architecture with future regulatory requirements in mind
- Monitor Costs: Implement cost tracking and alerts from day one
Implementation Roadmap
Phase 1: Foundation (Month 1-2)
Set up AWS infrastructure, deploy nf-core/sarek pipeline, establish data management practices
Phase 2: Expansion (Month 3-4)
Add RNA-seq and somatic variant calling pipelines, build web portal, implement monitoring
Phase 3: Optimization (Month 5-6)
Fine-tune cost optimization, implement advanced features, train team on self-service
Outcome
The company adopted our recommendations, resulting in:
$2M Immediate Savings
Avoided unnecessary upfront investment in hardware and software licenses. Redirected funds to R&D and hiring.
$7M 3-Year Savings
Total cost of ownership reduced from $8.1M to $1.1M over 3 years through strategic technology choices.
Faster Time to Market
Cloud-based infrastructure operational in 6 weeks vs. 6 months for on-premise HPC cluster.
Scalability & Flexibility
Architecture scales seamlessly from 50 to 500 genomes/month without infrastructure changes.
SyncBio's technology assessment saved us from making a $2M mistake. We were about to commit to expensive commercial software and hardware that we didn't need. Their recommendations gave us a modern, scalable infrastructure at a fraction of the cost, and the savings allowed us to extend our runway by 18 months.
Need Technology Assessment?
Let SyncBio evaluate your technology stack and identify opportunities for optimization and cost savings.
Schedule Assessment